The proponent companies commended the guidance’s focus on human contribution to determine patentability, while IBM and large drug lobbyist Biotechnology Innovation Organization voiced concern about how the agency will determine whether human contributions are “significant” enough to constitute inventorship. The comments were posted after the Monday deadline for feedback passed.
The patent office issued guidance in February explaining that AI-assisted ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.